Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(74,111) | $(55,339) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation expense | 408 | 207 |
| Equity-based compensation expense | 17,155 | 11,126 |
| Amortization of discounts on marketable securities | (1,549) | (2,379) |
| Non-cash lease expense | 980 | 857 |
| Changes in operating assets and liabilities: |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s D&A?
- Apogee Therapeutics, Inc. (APGE) reported D&A of $408K in Q1 2026.
- How has Apogee Therapeutics, Inc.'s D&A changed year-over-year?
- Apogee Therapeutics, Inc.'s D&A increased by 97.1% year-over-year, from $207K to $408K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Apogee Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude